Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIK3CD | O00329 | 17/20 | 0.38 |
| ▸ | PIK3R1 | P27986 | 5/20 | 0.38 |
| ▸ | PIK3CG | P48736 | 3/20 | 0.37 |
| ▸ | PIK3CB | P42338 | 3/20 | 0.34 |
| ▸ | PIK3CA | P42336 | 2/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5606961 | 0.92 | PIK3CD (0.43) | PIK3CDPIK3R1PIK3CGPIK3CBPIK3CA | |
| SCHEMBL5607473 | 0.91 | PIK3CD (0.41) | PIK3CDPIK3R1PIK3CGPIK3CBPIK3CA | |
| SCHEMBL5606889 | 0.90 | PIK3CD (0.41) | PIK3CDPIK3R1PIK3CGPIK3CBPIK3CA | |
| SCHEMBL5607928 | 0.89 | PIK3CG (0.41) | PIK3CDPIK3R1PIK3CGPIK3CBPIK3CA | |
| SCHEMBL5257195 | 0.89 | PIK3CD (0.37) | PIK3CDPIK3R1PIK3CGPIK3CBPIK3CA | |
| SCHEMBL5607754 | 0.89 | PIK3CD (0.48) | PIK3CDPIK3R1PIK3CGPIK3CBPIK3CA | |
| SCHEMBL5259222 | 0.88 | PIK3CD (0.40) | PIK3CDPIK3R1PIK3CGPIK3CBPIK3CA | |
| SCHEMBL5607940 | 0.88 | PIK3CD (0.47) | PIK3CDPIK3R1PIK3CGPIK3CB | |
| SCHEMBL5258821 | 0.88 | USP2 (0.43) | PIK3CDPIK3R1PIK3CG | |
| SCHEMBL5257938 | 0.87 | PIK3R2 (0.43) | PIK3CDPIK3R1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8980901-B2 | 5-fluoro-3-phenyl-2[1-(9H-purin-6-ylamino)propyl]-3H-quinazolin-4-one and 6-fluoro-3-phenyl-2-[1-(9H-purin-6-ylamino)ethyl]-3H-quinazolin-4-one as inhibitors of human phosphatidylinositol 3-kinase delta | ICOS CORPORATION (US) | 2015-03-17 | — | — | US | disclosed |
| US-20140121224-A1 | QUINAZOLINONES AS INHIBITORS OF HUMAN PHOSPHATIDYOSITOL 3-KINASE DELTA | ICOS CORPORATION (US) | 2014-05-01 | — | — | US | disclosed |
| EP-1750715-A1 | METHODS FOR TREATING MAST CELL DISORDERS | ICOS CORPORATION (US) | 2007-02-14 | — | — | EP | disclosed |
| WO-2005120511-A1 | METHODS FOR TREATING MAST CELL DISORDERS | ICOS CORPORATION (US) | 2005-12-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140121224-A1 | QUINAZOLINONES AS INHIBITORS OF HUMAN PHOSPHATIDYOSITOL 3-KINASE DELTA | PIK3CD, PIK3CB, PIK3CG | PIK3CD 1/4885PIK3R1 25/4885PIK3CG 3/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.